The Importance of Outcome Measure Research in Stargardt Disease
- PMID: 28542669
- PMCID: PMC8409797
- DOI: 10.1001/jamaophthalmol.2017.1544
The Importance of Outcome Measure Research in Stargardt Disease
Conflict of interest statement
Comment on
-
Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.JAMA Ophthalmol. 2017 Jul 1;135(7):696-703. doi: 10.1001/jamaophthalmol.2017.1162. JAMA Ophthalmol. 2017. PMID: 28542693 Free PMC article.
-
Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.JAMA Ophthalmol. 2017 Jul 1;135(7):687-695. doi: 10.1001/jamaophthalmol.2017.1121. JAMA Ophthalmol. 2017. PMID: 28542697 Free PMC article.
Similar articles
-
Fundus autofluorescence patterns in stargardt disease over time.Arch Ophthalmol. 2012 Oct;130(10):1354; author reply 1354-5. doi: 10.1001/archophthalmol.2012.1559. Arch Ophthalmol. 2012. PMID: 23044968 No abstract available.
-
Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.JAMA Ophthalmol. 2017 Jul 1;135(7):696-703. doi: 10.1001/jamaophthalmol.2017.1162. JAMA Ophthalmol. 2017. PMID: 28542693 Free PMC article.
-
Multimodal imaging and multifocal electroretinography demonstrate autosomal recessive Stargardt disease may present like occult macular dystrophy.Retina. 2014 Aug;34(8):1567-75. doi: 10.1097/IAE.0000000000000136. Retina. 2014. PMID: 24743636
-
Stargardt Disease.Adv Exp Med Biol. 2018;1085:139-151. doi: 10.1007/978-3-319-95046-4_27. Adv Exp Med Biol. 2018. PMID: 30578500 Review.
-
Novel therapeutics for Stargardt disease.Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1057-1062. doi: 10.1007/s00417-017-3619-8. Epub 2017 Mar 11. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28285324 Review.
Cited by
-
Reproducibility of Measurements of Retinal Structural Parameters Using Optical Coherence Tomography in Stargardt Disease.Transl Vis Sci Technol. 2019 Jun 21;8(3):46. doi: 10.1167/tvst.8.3.46. eCollection 2019 May. Transl Vis Sci Technol. 2019. PMID: 31259091 Free PMC article.
References
-
- Schönbach EM, Wolfson Y, Strauss RW, et al.; ProgStar Study Group. Macular sensitivity measured with microperimetry in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) study: Report No. 7 [published online May 25, 2017]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2017.1162 - DOI - PMC - PubMed
-
- Strauss RW, Muñoz B, Ho A, et al.; ProgStar Study Group. Incidence of atrophic lesions in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) study: Report No. 5 [published online May 25, 2017]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2017.1121 - DOI - PMC - PubMed
-
- Allikmets R, Singh N, Sun H, et al.A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15(3): 236–246. - PubMed
-
- Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci. 1995;36(3):718–729. - PubMed
-
- Fujinami K, Lois N, Mukherjee R, et al.A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci. 2013;54(13):8181–8190. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical